🇺🇸 FDA

Intelligence · Patent portfolio

United Therapeutics Europe Patents

Full USPTO pharma patent portfolio for United Therapeutics Europe — grant dates, expiration, and drug cross-links.

Patents
3,720
Expiring ≤24m
234

Quick answer

United Therapeutics Europe has 3,720 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 234 expire within 24 months — use filters for patent-cliff planning.

Page 35 of 78

  1. US 9273136

    Fully human anti-human NKG2D monoclonal antibodies

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9272009

    Method for increasing performance of offspring

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9272023

    Use of ixolaris, a tissue factor inhibitor, for inhibiting angiogenesis

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9273121

    Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9272027

    Francisella tularensis live vaccine strains and methods of use

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9265818

    Genetically modified Babesia parasites expressing protective tick antigens and uses thereof

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9266960

    Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9266928

    Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction

    Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9260504

    N- and C-terminal substituted antagonistic analogs of GH-RH

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9259463

    Chlamydia vaccine

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9259452

    Deacetylase inhibitor therapy

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9254316

    Adenoviral vector-based malaria vaccines

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9254319

    Compositions and methods for generating an immune response

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9248145

    Two alkylresorcinol synthase genes from sorghum; cloning, expression, transformation and characterization

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9249217

    Bispecific EGFRvIII x CD3 antibody engaging molecules

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9248179

    Pan-lyssavirus vaccines against rabies

    Expires Mon Jan 28 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9243051

    Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T-cells

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9241981

    Use of a food additive based on at least one phytonutrient for stimulating vaccine immunity against apicomplexa in animals

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9243036

    Anti-microbial activity of synthetic peptides

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9238684

    SPANX-B polypeptides and their use

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9238069

    Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9238800

    Avian adenoassociated virus and uses thereof

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9238799

    Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9233973

    Pharmaceutical compositions which inhibit FKBP52-mediated regulation of androgen receptor function and methods of using same

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9234179

    Materials and methods for generating pluripotent stem cells

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9228171

    Regulatory B cells (tBREGS) and their use

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9228002

    Leishmania vaccine using sand fly salivary immunogen

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9222086

    Compositions and methods for silencing genes expressed in cancer

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9220706

    Inhibition of leukemic stem cells by PP2A activating agents

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9222142

    Adenoviruses and their use

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9220261

    Volatile blends and the effects thereof on the navel orangeworm moth

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9216214

    Replication-competent adenoviral vectors

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9217010

    N-substituted indenoisoquinolines and syntheses thereof

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9216213

    Adjuvanted rabies vaccine with improved viscosity profile

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9211275

    Ketone bodies and ketone body esters as blood lipid lowering agents

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9211302

    Modulation of LRCH4 activity and therapeutic application thereof

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9210925

    Multipotent postnatal stem cells from human periodontal ligament and uses thereof

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9206154

    Inverse agonists and neutral antagonists for the TSH receptor

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9206240

    Pseudomonas exotoxin A with less immunogenic B cell epitopes

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9206245

    Immunogenic peptides and methods of use for treating and preventing cancer

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9206411

    Staphylococcal Phage2638A endolysin amidase domain is lytic for Staphylococcus aureus

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9206257

    Human monoclonal antibodies specific for glypican-3 and use thereof

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9205091

    Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9205276

    Light as a replacement for mitogenic factors on progenitor cells

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9198976

    Polysaccharide-protein conjugate vaccines

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9199908

    Compounds and methods for delivery of prostacyclin analogs

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9198941

    Yeast-Brachyury immunotherapeutic compositions

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9198645

    Controlled vesicle self-assembly in continuous two phase flow microfluidic channels

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does United Therapeutics Europe have?

3,720 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do United Therapeutics Europe patents expire?

234 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.